Drug Trial Radar · NCT00688688
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,792
Actual
Start
Apr 25, 2008
Primary completion
May 6, 2010
Study completion May 6, 2010
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 3, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
Conditions
- Urinary Bladder, Overactive
Interventions
MirabegronDrug
Tablets
TolterodineDrug
Extended release capsules
Placebo to MirabegronDrug
Matching mirabegron placebo tablets.
Placebo to TolterodineDrug
Matching tolterodine placebo capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs)Time frame: From the first dose of double-blind study drug up until 30 days after the last dose of study drug, up to 13 months.
Locations
308 sites in 30 countries. Site status is shown where the registry gives one.
Site not named
Homewood, Alabama
Site not named
Huntsville, Alabama
Site not named
Mobile, Alabama
Site not named
Montgomery, Alabama
Site not named
Anchorage, Alaska
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Atherton, California
Site not named
Beverly Hills, California
Site not named
Buena Park, California
Site not named
Fresno, California
Site not named
La Mesa, California
Site not named
Mission Hills, California
Site not named
Newport Beach, California
Site not named
Orange, California
Site not named
Sacramento, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
Tarzana, California
Site not named
Torrance, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Denver, Colorado
Site not named
Englewood, Colorado
Site not named
New Britain, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Aventura, Florida
Site not named
Clearwater, Florida
Site not named
Clearwater, Florida
Site not named
Fort Myers, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Pembroke Pines, Florida
Site not named
Pembroke Pines, Florida
Site not named
Sarasota, Florida
Site not named
Tallahassee, Florida
Site not named
Tampa, Florida
Showing 40 of 308 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.